Annals of Coloproctology

Display

Sort by :

Case Report

Malignant disease, Benign GI diease,Colorectal cancer,Complication

An Unusual Case of Colon Perforation With Multiple Transmural Ulcers After Use of Polmacoxib and Everolimus in a Metastatic Breast Cancer Patient: In-Gyu Song, Kyung Uk Jung, Hyung Ook Kim, Hungdai Kim, Ho-Kyung Chun; Ann Coloproctol. 2021;37(2):120-124. Published online March 16, 2020; DOI: https://doi.org/10.3393/ac.2019.08.17

6,078 View
128 Download
2 Web of Science
3 Citations

Everolimus (Afinitor) is an inhibitor of mammalian target of rapamycin. Polmacoxib (Acelex) is a nonsteroidal anti-inflammatory drug that belongs to the cyclooxygenase-2 (COX-2) inhibitor family and is mainly used for treatment of arthritis. Intestinal perforation has not been reported previously as a complication of everolimus, and perforation of the lower intestinal tract caused by a selective COX-2 inhibitor is extremely rare. We present here a case of colon perforation that occurred after use of polmacoxib in a metastatic breast cancer patient who had been treated with everolimus for the preceding six months.

Citations

Citations to this article as recorded by

Identification of Drugs Associated With Oral Ulcers Based on Pharmacovigilance
Xinyue Zhang, Xueqing Li, Wuda Huoshen, Shiting Li
International Dental Journal.2025; 75(6): 103957. CrossRef
Multiple ulcers and perforation of small intestine with everolimus use in a patient with rectal neuroendocrine tumor: A case report
Kentaro Abe, Shigenobu Emoto, Kazuhito Sasaki, Hiroaki Nozawa, Yoichi Yasunaga, Soichiro Ishihara
International Journal of Surgery Case Reports.2023; 106: 108094. CrossRef
Everolimus/polmacoxib

Reactions Weekly.2021; 1869(1): 157. CrossRef

First
Prev
Page of 1
Next
Last

Search